Delirium in ICU Patients: Diagnosis and Management
Routinely screen all ICU patients for delirium using the CAM-ICU or ICDSC tools, and prioritize non-pharmacological interventions—particularly early mobilization, light sedation, and sleep optimization—as these are the only strategies proven to reduce delirium incidence and duration. 1
Understanding the Stakes
Delirium in the ICU is not a benign, transient confusion—it directly increases mortality, prolongs ICU and hospital length of stay, and causes persistent post-ICU cognitive impairment 1. This makes aggressive prevention and early detection critical to patient outcomes.
Diagnosis: Systematic Screening
Validated Screening Tools
- Use CAM-ICU (Confusion Assessment Method for the ICU) or ICDSC (ICU Delirium Screening Checklist) as your primary screening instruments 1
- These are the most valid and reliable tools available, with strong evidence supporting their use
- Screen at least 4 times per shift and as needed 1
- Both tools can be administered by nurses and physicians with minimal training
What to Look For
Delirium manifests as:
- Acute onset of fluctuating mental status changes
- Inattention (inability to focus or maintain attention)
- Altered level of consciousness
- Disorganized thinking
Critical pitfall: Hypoactive delirium (quiet, withdrawn patients) is frequently missed because it doesn't disrupt workflow. These patients have the same poor outcomes as agitated patients but receive less intervention 2, 3.
Prevention: The Evidence-Based Approach
Non-Pharmacological Interventions (FIRST-LINE)
Early mobilization is the single most effective intervention 1. The 2025 SCCM guidelines specifically recommend enhanced mobilization/rehabilitation over usual care 4.
Implement these bundled interventions:
Mobilization Protocol
- Get patients out of bed as early as medically feasible
- Progressive activity: passive range of motion → sitting → standing → walking
- Reduces both incidence and duration of delirium 1
Sedation Management
Sleep Optimization
Cognitive Reorientation
Pain Management
- Treat pain first, then sedate (analgesia-first approach) 1
- Adequate analgesia reduces agitation and delirium risk
Pharmacological Prevention: What NOT to Do
Do not use haloperidol or atypical antipsychotics prophylactically to prevent delirium 1. The evidence shows no benefit, and this represents a strong guideline recommendation.
Risk Factor Modification
Identify high-risk patients with these baseline factors 1:
- Pre-existing dementia
- History of hypertension
- History of alcoholism
- High severity of illness at admission
- Coma
- Benzodiazepine use
Actionable step: Avoid or minimize benzodiazepines in these patients—this is a modifiable risk factor with strong evidence 1.
Treatment: Once Delirium Develops
The Disappointing Reality of Pharmacotherapy
There is no compelling evidence that any medication reduces the duration of delirium 1. This is a critical point that differs from common practice:
- Haloperidol: No published evidence of benefit 1
- Atypical antipsychotics: May reduce duration (weak evidence, grade C) 1
- Rivastigmine: Do NOT use—associated with harm 1
When to Consider Antipsychotics
Use antipsychotics only for:
- Severe agitation that prevents necessary care
- Risk of harm to patient or staff
- Hyperactive delirium with distressing hallucinations 6
Critical safety consideration: Withhold antipsychotics in patients with 1:
- Baseline QT prolongation
- History of Torsades de Pointes
- Concurrent QT-prolonging medications
Sedation in Delirious Patients
If sedation is required in a delirious patient, use dexmedetomidine rather than benzodiazepines 1.
Exception: Alcohol or benzodiazepine withdrawal delirium—these patients require benzodiazepines for the underlying withdrawal syndrome 1.
Practical Implementation Algorithm
- Screen all ICU patients for delirium using CAM-ICU or ICDSC (≥4 times/shift)
- If delirium detected:
- Identify and treat underlying causes (infection, metabolic derangement, hypoxia)
- Intensify non-pharmacological bundle (mobilization, reorientation, sleep hygiene)
- Review and minimize deliriogenic medications (especially benzodiazepines)
- Optimize pain control
- If severe agitation:
- Check QTc before antipsychotics
- Consider low-dose haloperidol or atypical antipsychotic
- If sedation needed: use dexmedetomidine (unless withdrawal-related)
- Never use medications prophylactically to prevent delirium
Common Pitfalls to Avoid
- Failing to screen hypoactive patients: They appear "calm" but have equally poor outcomes
- Using benzodiazepines for agitation: This worsens delirium except in withdrawal syndromes
- Prophylactic antipsychotics: No evidence of benefit, potential for harm
- Over-sedation: Light sedation targets improve outcomes
- Ignoring environmental factors: Sleep disruption and immobility are modifiable contributors
The Bottom Line
The evidence strongly supports a prevention-focused, non-pharmacological approach centered on early mobilization, light sedation, and environmental optimization. Medications have minimal role in prevention and limited evidence for treatment. The 2013 PAD guidelines [1-1] remain the foundation, with the 2025 SCCM update 4 reinforcing these principles and adding conditional support for dexmedetomidine over propofol for sedation and melatonin for sleep.